PYC Therapeutics
Manufacturing · Australia · 51-200 Employees
View Company Info for Free
Overview
Headquarters
6 Verdun St Harry Perkins Institute, Ned...Phone Number
+61861510992Website
www.pyctx.comRevenue
$26.2 MillionStock Symbol
PYCIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About PYC Therapeutics
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which is in pre-clinical studies; and PYC-003 to treat autosomal dominant polycystic kidney disease, which is in early-stage clinical trials. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders.Explore more
PYC Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PYC Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at PYC Therapeutics
Earning: See what the market has to say on PYC Therapeutics recently announced quarterly report
Check out if PYC Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once PYC Therapeutics has new funding data
Click to see if PYC Therapeutics had a recent Job posting/layoffs
Check if PYC Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when PYC Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
PYC Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to PYC Therapeutics
Compare insights from companies similar to PYC Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
PYC Therapeutics
$26.2M
51-200
Public
$121.6M
2005
CR
Carol RichardsonCEO & Eo To The Accounts & HR Administrator
Company Profile Activity
Activity Insights
PYC Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
PYC Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about PYC Therapeutics.
PYC Therapeutics financials insights
Gather financial insights about PYC Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Other Financing Round
$74.6M
2026
Stock/Share Issuance
$47M
PYC Therapeutics Tech Stack
A closer look at the technologies used by PYC Therapeutics
Most Recent Scoops
Project
PYC Therapeutics has completed a pre-IND meeting with the U.S. FDA for its polycystic kidney disease program, aligning on a clinical development pathway in which the Phase I-A/I-B study is directly enabling of a Phase III transition, with a Type C meeting planned for the second half of this year to confirm this enabling link on the basis of Phase I-A data and available Phase I-B MAD study data.
Pharmaceuticals, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
PYC Therapeutics News & Media
PYC Therapeutics secures strong backing as retail offer adds $47 million to capital raise
PYC Therapeutics (ASX:PYC) has completed the retail component of a major capital raising, adding approximately $47 million to its funding as the biotechnology company continues to advance its precision medicine programs for genetic diseases.When Will PYC Therapeutics Limited (ASX:PYC) Become Profitable?
We feel now is a pretty good time to analyse PYC Therapeutics Limited's ( ASX:PYC ) business as it appears the company...PYC Therapeutics Secures $146 Million in Entitlement Offer to Advance RNA Therapies
An announcement from PYC Therapeutics Limited ( ($AU:PYC) ) is now available. PYC Therapeutics Limited has successfully completed its Entitlement Offer, raising app...PYC Therapeutics Secures $146 Million to Advance Drug Pipeline - TipRanks.com
PYC Therapeutics Limited ( ($AU:PYC) ) just unveiled an announcement. PYC Therapeutics Limited has successfully completed the institutional component of its Entitle...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding PYC Therapeutics
Sign Up For FreeTo access detailed company insights
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding... Read More
